Tiziana Life Sciences Ltd (TLSA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Tiziana Life Sciences Ltd (TLSA) closed at USD 1.05 on 2026-10-14, a change of -46.2 % over the past year, with a market capitalization of USD 133.62M.

Tiziana Life Sciences Ltd recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Tiziana Life Sciences Ltd key figures

Previous close

USD 1.05 (2026-10-14)

1-year change

-46.2 %

Market cap

USD 133.62M

Enterprise value

USD 122.98M

P/E ratio (trailing)

-7.00

P/E ratio (forward)

-5.84

EPS (trailing)

-0.15

EPS (forward)

-0.18

PEG ratio

n/a

Price to book

n/a

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.97

Employees

10

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Tiziana Life Sciences Ltd and compare it with other stocks.